PedAM
Pediatric Disease Annotations & Medicines
| Disease | breast cancer |
| Symptom | |bone metastases |
| Sentences | 118 |
| PubMedID- 25070686 | (177)lu-edtmp for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase ii study. |
| PubMedID- 20882405 | Sixty breast cancer patients with bone metastases were randomized to receive either zoledronic acid 1 mg iv weekly for 4 doses or a single dose of zoledronic acid 4 mg iv. |
| PubMedID- 21727006 | Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial. |
| PubMedID- 24895505 | Usefulness of (18)f-fluoride pet/ct in breast cancer patients with osteosclerotic bone metastases. |
| PubMedID- 24790656 | In contrast to bs and fdg pet-ct, 18f-naf pet-ct has clearly shown superior sensitivity for the detection of bone metastases in patients with breast cancer and other malignancies. |
| PubMedID- 26514321 | Detection of bone metastases in breast cancer patients in the pet/ct era: do we still need the bone scan. |
| PubMedID- 24687563 | The aim of this retrospective analysis of breast cancer patients with bone metastases was to systematically assess the bone lesions in terms of stability, fractures prior to and following rt, survival, and predictive factors for stability. |
| PubMedID- 23788976 | We have demonstrated that fas ligand expression in the primary tumor was considerably less frequent among breast cancer patients with bone metastases compared to women without skeletal spread . |
| PubMedID- 21542414 | breast cancer patients with bone metastases enrolled in a randomized, double-blind, phase iii study comparing denosumab with zoledronic acid for preventing skeletal related events and completed the bpi-sf, fact-b, and eq-5 datbaseline, week 5, and monthly through the end of the study. |
| PubMedID- 21527062 | Denosumab also demonstrated clinical efficacy in delaying or preventing skeletal-related events (sres) in breast cancer patients with bone metastases. |
| PubMedID- 23989945 | One trial evaluating community bisphosphonate infusions in breast cancer patients with bone metastases reported significant improvements in pain, general activity, physical, role and social functioning when compared with hospital delivery (wardley et al, 2005), but financial implications were not addressed. |
| PubMedID- 25342482 | These biochemical markers can be used for prognosis and optimization of therapy for bone metastases in patients with breast cancer. |
| PubMedID- 21417901 | Stopeck at, lipton a, body jj et al.: denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. |
| PubMedID- 25189922 | Background: we assessed the effect of zoledronic acid on quality of life (qol) and pain outcome in breast cancer patients with bone metastases using the european organization for research and treatment of cancer bone metastases module (eortc qlq-bm22). |
| PubMedID- 23935856 | bone metastases, present in 70% of patients with metastatic breast cancer, lead to skeletal disease, fractures and intense pain, which are all believed to be mediated by tumor cells. |
| PubMedID- 22977313 | Skeletal related events (sre) are relatively common and severe consequences of cancers that have metastasized to bone, in particular for solid cancers of the prostate, breast, or lung.1 jensen et al reported a cumulative 5-year incidence of sres among breast cancer patients with bone metastases of 51.7% (95% confidence interval ci 48.9–54.4).2 intravenous bisphosphonates, usually administered during hospitalization, are one of the cornerstone methods of sre prevention.3 bisphosphonates inhibit osteoclast activity and reduce skeletal morbidity by 30%–60% in patients with metastatic bone disease.3 in addition, bisphosphonates are also used for treatment of hypercalcemia in cancer patients. |
| PubMedID- 21953212 | Fdg-avid sclerotic bone metastases in breast cancer patients: a pet/ct case series. |
| PubMedID- 20504320 | In summary, pre-clinical studies in several different syngeneic as well as allogeneic mammary cancer models have provided convincing evidence that targeting the tgf-β pathway using either a tgf-β neutralizing antibody or receptor kinase inhibitors can inhibit both early lung and bone metastases of basal-like breast cancer. |